- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02343887
CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy (CogStim)
Despite undetectable plasma viral load under treatment, about 30% of HIV infected patients show asymptomatic neurocognitive impairment or minor cognitive disorder. These symptoms impact the compliance of the treatment, though its performance and daily life quality. To this day, no therapy tested has proved its efficiency, including the strategy of the antiretroviral therapy (cART) optimization according to the Cerebral Penetration effectiveness Score (CPE).
Description of the study: an open prospective comparative monocentric pilote study, randomised in three groups which investigates the efficiency of a 6 months-cognitive rehabilitation program on improving asymptomatic or minor cognitive disorder for undetectable HIV+ patients. This study gathers HIV-1 patients undetectable under stable cART with a good cerebral penetration who develop asymptomatic or minor cognitive disorders connected to HIV infection. Those who have severe psychiatric disorder or who are on medication that could interfere with psychometrical tests will be excluded.
Main Objective: to compare the impact of a cognitive rehabilitation program over a 6 months period on the evolution of minor cognitive disorders and asymptomatic patients to a control group and a group treated with psychological support.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Paca
-
Marseille, Paca, France, 13354
- Recruiting
- Assistance Publique Hopitaux de Marseille
-
Contact:
- olivia zaegel
- Email: olivia.zaegel@ap-hm.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- - Seropositive for HIV-1 Patient
- With a plasma viral load below the limit of detection for minimum 6 months (HIV viral load <40 copies / ml)
- On stable antiretroviral therapy for 12 months, according to the revised optimized subject to the constraints of genotypic resistance and CPE score in the absence of cons-indication to treatment intensive brain penetration (Annex 15)
- With cognitive complaint objectified by the cognitive complaint questionnaire (Appendix 9: score 3 or 1 positive response among the items C4, C5, C7, C8) and cognitive impairment found by an alteration of at least two cognitive fields assessed by psychometric tests for at least 6 months
- 18 <age <55 years
- No defined by a marked depression scale score of Beck <16 (Appendix 13)
- No marked anxiety defined by a T score> 55 on the scale of Spielberger STAI-Y (Annex 14)
- Insured under the social security
- Who signed the consent form.
- Recent brain imaging excluding other causes of cognitive impairment (MRI or CT brain injected injected so-indication against MRI)
Exclusion Criteria:
- A patient diagnosed and followed for more than six months psychiatric disorder that could interfere with psychometric assessment
- Patients with a poor understanding of French,
- Patients with active opportunistic infection of the CNS or with neurological sequelae.
- History of head trauma
- Active Substance excluding cannabis
- Patient for which a change of antiretroviral therapy is provided within 12 months
- Patient for which interferon treatment is provided within 12 months
- Patient placed under guardianship,
- Patient with HIV-related dementia
- Liver cirrhosis Child B or C (Annex 16)
- Severe renal impairment (creatinine clearance by Cockcroft <30 ml / min)
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: control group
patients without taking into cognitive or psychological treatment for 6 months (period 1) and
|
|
Experimental: group with cognitive rehabilitation,
patients treated for 6 months Cognitive remediation (period 1), then
|
|
Experimental: group with psychological support.
patients treated with counseling for six months (period 1) and
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cognitive remediation strategy (BREF test)
Time Frame: 6 months
|
- BREF test
|
6 months
|
cognitive remediation strategy (grooved pegboard test)
Time Frame: 6 months
|
- grooved pegboard test
|
6 months
|
cognitive remediation strategy (RLRI-16 test6.)
Time Frame: 6 months
|
- RLRI-16 test6.
|
6 months
|
cognitive remediation strategy (Digit Symbol Substitution Test)
Time Frame: 6 months
|
- Digit Symbol Substitution Test
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
impact on daily life quality (SF-12 Medical Outcomes Study Short-Form General Health Survey)
Time Frame: 6 months
|
SF-12 Medical Outcomes Study Short-Form General Health Survey"
|
6 months
|
impact on daily life quality (Trail Making Test)
Time Frame: 6 months
|
-Trail Making Test
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2013-49
- 2013-A01621-44 (Other Identifier: ansm)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on neuropsychological tests
-
University Hospital, GrenobleUnknownAttention Deficit-HyperactivityFrance
-
Istituto Auxologico ItalianoRecruiting
-
Hospices Civils de LyonCompleted
-
Association pour le Développement et l'Organisation...Association Française du Syndrome d'Ondine; Fonds de Recherche en Santé RespiratoireCompletedHealthy | Amyotrophic Lateral Sclerosis | Ondine SyndromeFrance
-
South Tees Hospitals NHS Foundation TrustUnknown
-
University Medical Center GroningenNot yet recruitingCognitive Dysfunction | Glioma, Malignant
-
University Hospital, Clermont-FerrandRecruiting
-
Rennes University HospitalRecruitingNeurological Diseases | Central Nervous SystemFrance
-
University Hospital, BordeauxCompletedAttention-Deficit/Hyperactivity DisorderFrance
-
University Hospital, CaenUnknown